Key result
Insulin therapy in NIDDM patients was associated with significant increases in systolic (131.8 to 148 mmHg, P<0.05) and diastolic (80.9 to 89.2 mmHg, P<0.02) blood pressures compared to controls.
Why the study?
Does insulin therapy increase blood pressure in NIDDM patients with secondary failure to oral hypoglycemic agents?
Cohort (n=160)
Does insulin therapy increase blood pressure in NIDDM patients with secondary failure to oral hypoglycemic agents?
p-value: p=<0.05
Initiation of insulin therapy in NIDDM patients with secondary failure to oral agents is associated with significant elevations in both systolic and diastolic blood pressures.
May warrant BP monitoring upon insulin initiation in NIDDM; leaves open causality and needs prospective trials.
OBJECTIVE: To assess the effect of insulin therapy on blood pressure in NIDDM patients with secondary failure. RESEARCH DESIGN AND METHODS: The influence of insulin treatment on blood pressure was assessed retrospectively in a group of 80 NIDDM patients with secondary failure to diet and maximum doses of oral hypoglycemic agents. Weight, blood glucose, and blood pressure were recorded over a 3-mo period before and after the initiation of insulin therapy. RESULTS: There was a significant rise in systolic (131.8 +/- 1.7 to 148 +/- 1.9 mmHg, P less than 0.05) and diastolic (80.9 +/- 0.9 to 89.2 +/- 1.0 mmHg, P less than 0.02) blood pressures with insulin treatment. Insulin treatment was associated with a significant decrease in blood glucose (18.36 +/- 0.28 to 10.4 +/- 0.34 mM, P less than 0.01) and an increase in weight (72.1 +/- 1.6 to 78 +/- 1.7 kg, P = 0.01). A control group of 80 NIDDM patients matched for age, weight, BMI, and duration of diabetes demonstrated no significant change in blood pressure over a matched period of follow-up. CONCLUSIONS: This study has shown that insulin therapy is associated with significant elevation of both systolic and diastolic blood pressures.
No takes yet. Share an insight, caveat, or question.
Randeree et al. (1992) conducted a cohort in NIDDM with secondary failure (n=160). Insulin therapy vs. Matched control group of NIDDM patients was evaluated on Change in systolic and diastolic blood pressure (p=<0.05). Insulin therapy in NIDDM patients was associated with significant increases in systolic (131.8 to 148 mmHg, P<0.05) and diastolic (80.9 to 89.2 mmHg, P<0.02) blood pressures compared to controls.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: